

Stem cell ageing: does it happen and can we intervene?

Ilaria Bellantuono^{1,*} and W. Nicol Keith²

Adult stem cells have become the focus of intense research in recent years as a result of their role in the maintenance and repair of tissues. They exert this function through their extensive expansion (self-renewal) and multipotent differentiation capacity. Understanding whether adult stem cells retain this capacity throughout the lifespan of the individual, or undergo a process of ageing resulting in a decreased stem cell pool, is an important area of investigation. Progress in this area has been hampered by lack of suitable models and of appropriate markers and assays to identify stem cells. However, recent data suggest that an understanding of the mechanisms governing stem cell ageing can give insight into the mechanism of tissue ageing and, most importantly, advance our ability to use stem cells in cell and gene therapy strategies.

Stem cells are defined by their ability to give rise to new stem cells (self-renewal) and to differentiate into one or more mature specialised cells of a tissue. There are two types of stem cells: embryonic stem cells and adult stem cells. In vivo, embryonic stem cells constitute the inner cell mass of an early-stage embryo and undergo complete differentiation into the three germ layers within a few days; when isolated from early embryos they possess extended proliferative capacity and the potential to differentiate into all tissues derived from the three germ layers (Refs 1, 2). Adult stem cells have been isolated from various tissues – including bone marrow (Ref. 3), skin (Ref. 4), gut (Refs 5, 6), muscle (Ref. 7), brain (Ref. 8), liver (Ref. 9), breast (Ref. 10) and pancreas (Ref. 11) – but their capacity for expansion and

multilineage differentiation is thought to be more limited. Adult stem cells are thought to function in maintenance and repair of tissues throughout the lifespan of the individual. Indeed, some adult tissues require extensive proliferation and tissue replacement to survive: in physiological conditions the entire intestinal lining fully replaces itself weekly and the bone marrow produces 10^8 cells daily.

Adult stem cells and self-renewal

The process by which stem cells give rise to terminally differentiated cells occurs through a variety of committed progenitor cells (or transient amplifying cells), often overlapping in their differentiation capacity. During commitment, stem cells can undergo extensive proliferation and sequential differentiation, accompanied by a

¹Academic Unit of Bone Biology, University of Sheffield Medical School, Sheffield, S10 2RX, UK.

²Centre for Oncology and Applied Pharmacology, University of Glasgow, Cancer Research UK Beatson Laboratories, Glasgow, G61 1BD, UK.

*Corresponding author: Ilaria Bellantuono, Room EU28, Academic Unit of Bone Biology, University of Sheffield Medical School, Beech Hill Rd, Sheffield, S10 2RX, UK. Tel: +44 (0)114 2711798; Fax: +44 (0)114 2711711; E-mail: i.bellantuono@shef.ac.uk

decrease in self-renewal capability to produce mature cells. The primary function of this transit population is to increase the number of mature cells produced by each stem cell division.

Self-renewal is defined by a cell division where at least one of the daughter cells retains the identical developmental potential as the mother cell. In principle, this property allows an identical stem cell pool to be maintained throughout the life of the individual, and thus provision of differentiated cells to repair the losses occurring in tissues with time (and hence maintenance of tissue function). Maintenance of the stem cell pool is achieved only if stem cell self-renewal occurs without a change in the genome during DNA replication. This guarantees preservation of the ability to generate the same types and numbers of differentiated progenitors. For decades it has been a common belief that the ability of stem cells to self-renew was, if not indefinite, very extended and that the stem cell pool was maintained for long periods of time. This was based on early experiments where haematopoietic stem cells (HSCs) were shown to be able to serially repopulate up to five mice (Ref. 12), suggesting that the few transplanted HSCs were able to undergo extensive self-renewal. In support of this was the concept of asymmetric cell division and the immortal strand formulated by John Cairns in 1975. This proposed that during division adult stem cells would be able to distinguish and segregate the parental chromatids from the newly synthesised ones and retain the parental strands; in this way stem cell DNA would not bear errors that may occur during DNA replication (Refs 13, 14 and references therein).

However, despite the extensive self-renewal property of adult stem cells, more recently the notion of stem cell ageing has emerged. Data suggest that with age the process of self-renewal and differentiation are affected, resulting in the generation of differentiated progeny but in fewer numbers or in the generation of progeny skewed towards one particular lineage (Refs 15, 16) (Figs 1 and 2). Asymmetric cell division has been observed in a very limited number of cell types and the experimental evidence is weak (Ref. 14). By contrast, more convincing evidence have been recently presented suggesting that there is an accumulation of changes in the DNA of stem cells with time, which may affect their functionality (Ref. 17). If DNA changes




Figure 1. Proposed self-renewal and differentiation capacity in ageing adult stem cells. If stem cells age, self-renewal capacity and/or potential for multilineage differentiation may be reduced over time and/or replication cycles. A threshold may then be reached that is inconsistent with efficient normal tissue or organ function.

reach a certain threshold, stem cells may undergo apoptosis or senescence, with increased cellular losses and decreased stem cell numbers. Alternatively, stem cells with DNA changes may escape senescence and have an increased risk of undergoing clonal change (Fig. 2).

Although evidence for some of these processes is well described, others remain more hypothetical. Moreover, it is unclear whether these changes occur in stem cells as part of a physiological process or only in circumstances of extreme stress, and whether it is the result of a programme intrinsic to stem cells or of changes in the microenvironment in which they reside. It is also a matter of debate whether it is in any way related or causal to the ageing of tissues and eventually loss of their function or alternatively may predispose to development of malignancy. In this review, we discuss the literature available in these areas.

Mechanisms of ageing

Ageing is seen as a side effect of mechanisms that are in place to limit carcinogenesis (Refs 18, 19, 20). Cells are provided with two defence mechanisms to limit cell proliferation and protect themselves from transformation when

Stem cell ageing: does it happen and can we intervene?




Figure 2. Model of stem cell proliferation and ageing. (a) Young stem cells – depicted here as haematopoietic stem cells – undergo self-renewal, which allows maintenance of the stem cell pool and production of all the differentiated effector cells required. (b) The accumulation of mutations in the DNA with age leads to an increased loss of stem cells and decreased ability to produce new stem cells, with a net decrease in stem cell number. Moreover, stem cells lose their ability to differentiate into all lineages. Increased cellular loss occurs by apoptosis or senescence when cells accumulate mutations in the DNA to a critical level. Such mutated stem cells that escape apoptosis or senescence become at risk of malignant transformation.

exposed to inappropriate stimuli: senescence and apoptosis. While the molecular mechanisms that limit cell proliferation by cell loss through apoptosis are well understood, the contribution of senescence to the ageing processes remains unclear. Moreover, the diverse signalling pathways that cause cells to choose between apoptosis and senescence are controversial (reviewed in Ref. 21). This is mainly because of the lack of reliable markers for the identification of senescent cells.

It is still controversial whether senescence occurs *in vivo* or only *in vitro*. Recently, evidence of *in vivo* senescence has been emerging based on multiple parameters. Senescent cells have been identified in ageing human skin (Ref. 22), and human and mouse liver (Refs 23, 24, 25, 26). Senescent cells were considered as such when they were metabolically viable but irreversibly arrested in

the G1 phase of the cell cycle, had undergone morphological changes (enlarged and flattened morphology), and expressed the senescence-associated β -galactosidase, higher levels of the tumour suppressors p21^{CIP1/WAF1} (encoded by *CDKN1A*) and p16^{INK4a} (encoded by *CDKN2A*) and hypophosphorylated retinoblastoma (Rb) protein.

Several pathways control cell proliferation (Fig. 3), including the p16^{INK4a}-Rb pathway, the p19^{ARF}-p53 pathway and the p53-p21^{CIP1/WAF1} pathway (hereafter named as p16, p19 and p21) (reviewed in Refs 27, 28). These pathways can be activated by telomere shortening or dysfunction (Ref. 27) or by a variety of stresses such as DNA damage and oncogenic insults (Ref. 29). More recently, the PTEN-p27^{Kip1} (hereafter named p27) pathway has also emerged as important in controlling cell proliferation (Ref. 30; reviewed in

Stem cell ageing: does it happen and can we intervene?




Figure 3. Examples of cell signalling pathways implicated in adult stem cell ageing. The figure shows possible relationships between cellular processes such as oxidative stress and telomere dysfunction via signalling pathways through to outcomes such as cellular senescence, apoptosis and cell cycle control. Pathway analysis was carried out using using Metacore MapEditor (GeneGo Inc: <http://www.genego.com>). The signalling pathways include gene products now associated with cellular senescence (p21, p27 and p16), and possible links to genes and proteins implicated in progeroid syndromes [e.g. Werner syndrome (WRN), Cockayne syndrome B; see Table 1] and stem cell ageing (see Table 2) are indicated. Red arrows show inhibitory effects; turquoise arrows show activation; grey arrows indicate unknown effect of interaction. Abbreviations: B, binding event; CM, covalent modification; P, phosphorylation event; TR, transcription regulation. Details on individual genes can be found at the GeneCards website: <http://www.genecards.org/index.shtml>.

Ref. 31). It is beyond the scope of this review to fully cover developments in this field, but the most important aspects in relation to stem cells are summarised here.

Replicative senescence was first described by Hayflick in 1961 (Ref. 32). The biological clock underlying the limited potential of somatic cells is the length of telomeres (the repeated DNA sequence at the end of each chromosome). Telomeres provide stability to the chromosomes and protect them against DNA loss associated with cell division (Ref. 33). Telomeres progressively shorten in all somatic cells at each cell division (Refs 34, 35). When

telomeres reach a critical short length, cells undergo replicative senescence (Refs 32, 34). Telomere length can be maintained by the enzyme telomerase (Ref. 36), but most adult somatic cells lack this enzyme. Stem cells, T cells and germ cells express it at different levels.

An alternative mechanism to replicative senescence is stress-induced senescence, which is independent of telomere length (Refs 37, 38). It can be induced by telomere dysfunction [which can occur when telomeres undergo a change of state (uncapping) or structure or DNA sequence], or as a result of DNA damage, oncogenic insults, and oxidative damage to

Stem cell ageing: does it happen and can we intervene?

Table 1. Progeroid syndromes and the investigation of stem cell ageing^a

Syndrome	Genetic abnormality	Lifespan (years)	Stem cells investigated
Down	Trisomy 21	~60	HSCs in human
Werner	Mutation in <i>WRN</i> ; autosomal recessive	~47	NA
Cockayne	Mutation in <i>ERCC8</i> and <i>ERCC6</i> ; autosomal recessive	~20	NA
Hutchinson–Gilford	Mutation in laminin A; autosomal recessive	~12	Ref. 150
Ataxia telangiectasia	Mutation in <i>ATM</i>	~20	HSCs, NSCs in murine model
Berardinelli–Seip	Mutations in <i>AGPAT2</i> or <i>BSCL2</i>	~40	NA
Rothmund–Thomson	Mutation in <i>RECQL4</i>	Normal?	NA
Tricothiodystrophy	Mutations in <i>XPB</i> and <i>XPD</i>	~10	NA
Xeroderma pigmentosum	Mutations in <i>XPA</i> and <i>XPG</i>	~40	NA
Bloom syndrome	Mutation in <i>BLM</i> helicase	~20	NA

^aFor reviews on progeroid syndromes, see Refs 151 and 152. Abbreviations: HSC, haematopoietic stem cell; NA, not applicable; NSC, neural stem cell. Information on genes mentioned in the table can be found at <http://www.genecards.org/index.shtml>.

cellular constituents leading to accumulation of abnormal proteins, lipid and macromolecule. The importance of these mechanisms in ageing are illustrated by progeroid (premature ageing) syndromes, most of which are due to single gene defects in one of the DNA repair enzymes or structural proteins of the nuclear membrane (Table 1).

Replicative senescence occurs mainly via the p21 pathway, and stress-induced senescence via p16 and/or p19 (Refs 28, 39). Interestingly, both p16 and p19 pathways are controlled by a transcription factor repressor of the Polycomb group gene family called BMI-1, which has been shown to be important in the self-renewal of neural stem cells and HSCs (Refs 40, 41, 42). BMI-1 induces cell progression into S phase of the cell cycle by blocking p16 and p19 (Refs 43, 44). BMI-1 was recently shown to be a direct transcriptional target of MYC and Sonic Hedgehog (SHH), which are also important in stem cell self-renewal. Decreased MYC led to decreased BMI-1, increasing the probability of

switching on p16 (Ref. 45). Moreover, SHH was shown to control proliferation through BMI-1-mediated repression of p16 and p19 (Ref. 46).

PTEN (phosphatase and tensin homologue) is a phosphatase that negatively regulates phosphoinositide 3-kinase (PI3K) signalling (Ref. 47; reviewed in Ref. 48). PTEN thus inhibits growth factors signals that act through PI3K. Among the downstream signalling molecules, AKT is the most characterised. This in turns acts on cell cycle regulators p27 and p21 and induction of senescence (Fig. 3). The PTEN–PI3K/AKT signalling pathway also interacts with signalling pathways known to be essential for stem cell self-renewal, including the transforming growth factor (TGF)- β –SMAD pathway and the WNT/ β -catenin pathway.

Detecting ageing in stem cells

To define whether stem cells undergo ageing, suitable methods to assess stem cell numbers and function are required. Moreover, as any ageing phenotype develops over time, suitable

Stem cell ageing: does it happen and can we intervene?

Table 2. Effects of changes in expression of tumour suppressor genes in stem cells

Gene modification	Stem cell examined	Outcome	Refs
p16 ^{-/-}	HSC	Modest increase in HSC pool in serial transplantation and by immunophenotype	102, 103
p16 ^{-/-}	NSC	Increased frequency of cells with neurosphere-formation ability in the SVZ of old mice	104
p19 ^{-/-}	HSC	No effect	102
p18 ^{-/-}	HSC	Marked increase in HSC pool in serial transplantation	105, 106
p21 ^{-/-}	HSC	Initial increase in HSC pool followed by exhaustion	106, 107, 108
p21 ^{-/-}	NSC	Increase in neurosphere formation in adult young mice followed by decrease in older mice	109
p53 ^{-/-}	HSC	Increased competitive repopulation ability in young mice	110
p53 ^{-/+}	HSC	Mild decreased HSC reconstitution ability in transplantation in older mice	110
p53 hyperactive	HSC	Reduction of HSC reconstitution ability in older mice	110
p27 ^{-/-}	HSC	Modest increase in HSC pool in serial transplantation	111, 112
PTEN ^{-/-}	HSC	Decline in reconstitution ability. Development of myelodysplastic disorder	113
Rb conditional ^{-/-}	HSC	Mild anaemia	119

Abbreviations: HSC, haematopoietic stem cell; NSC, neural stem cell; SVZ, forebrain lateral ventricle subventricular zone. For gene information, refer to section 'Mechanisms of ageing' and <http://www.genecards.org/index.shtml>.

Stem cell ageing: does it happen and can we intervene?

models that allow monitoring of stem cell numbers and function for a long period of time need to be identified. However, this is difficult to achieve because of technical difficulties in the identification of stem cells and differences in ageing mechanisms in different species, particularly mouse and human. It is important to understand the limitations of the assays and models available to be able of interpret the often contrasting data. To date, the majority of data available on ageing in stem cells are in relation to HSCs. Limited data are available in other stem cell systems, such as epithelial stem cells, neural stem cells, satellite cells and mesenchymal stem cells.

Identification of stem cells

The identification, isolation and enumeration of stem cells are elusive. Identification of stem cells is carried out by immunophenotype, by their ability to retain a dye due to their relative quiescent state or by their location, such as in the case of epithelial stem cells in the bulge and basal lamina or intestinal stem cells in the crypt. However, none of those methods is able to identify stem cells uniquely and to differentiate them from the transient amplifying cells. HSCs are the most extensively characterised type of stem cells (reviewed in Ref. 49).

Several markers have been proposed for HSCs, such as CD34. CD34 is expressed on 0.5–5.0%

of human bone marrow cells, is found on early haematopoietic progenitor cells but not on their mature counterparts, and has been used to provide cells that achieve clinical engraftment following transplantation (Refs 50, 51). Other surface markers have been used in the laboratory in association with CD34 to identify more-primitive populations of HSCs, such as CD34⁺CD38^{low} cells (Refs 52, 53). However, even with the most rigorous combination of markers only a small percentage of enriched cells are bona fide stem cells, which replicate infrequently but have the capacity of extended growth and when transplanted are responsible for long-term engraftment (Refs 49, 54, 55, 56). The majority of the cells are progenitor (or transient amplifying) cells, which replicate frequently but cycle only a limited number of times before undergoing terminal differentiation, and on transplantation provide at best only short-term engraftment (Refs 54, 55, 56, 57).

Other stem cells types are even less characterised in terms of markers. Although knowledge of epithelial stem cells and satellite cells has advanced at a fast pace in the past five years, prospective isolation is still in its infancy and is based on a combination of markers such as presence of the marker CD34, ability to retain bromodeoxyuridine (5-bromo-2-deoxyuridine; BrdU) over time, integrin expression levels for epithelial stem cells (Ref. 58), and properties of size and granularity for satellite cells (Ref. 7). This results at best only in enrichment for multipotent epithelial or satellite cells. Neural stem cells and mesenchymal stem cells are isolated by selective culture conditions. Very little is known about markers to isolate and enrich these stem cell types (Refs 59, 60, 61, 62). More-detailed studies employing prospective isolation and clonal marking are required to define the precise lineage progression of these stem cell populations.

The alternative to enumeration of stem cells is to rely on a range of functional in vitro and in vivo assays (Fig. 4). These have been well developed over the last 20–30 years in an attempt to identify HSCs. In vitro assays assess cells based on their proliferative capacity and retention of multipotent differentiation. In vivo assays assess the ability of stem cells to repopulate tissues with cells of multiple lineages in a host depleted of stem cells (e.g. lethally irradiated in the case of HSCs) before transplantation.




Figure 4. Identification of stem cells. Cell-surface markers can be used to enrich for rare stem cells (red) within populations. However, functional assays are then required to confirm stem cell properties of self-renewal and lineage commitment (in vitro and in vivo assays). In vitro assays are based on the extent of the clonogenic capacity of the progenitor cells and their multilineage differentiation. In vivo assays are based on transplantation and assessment of tissue reconstitution.

Transplantation of limiting dilution numbers of stem cells in a competitive repopulating assay allows a quantitation of the stem-cell-repopulating unit present in a transplanted population. The analysis of the types and numbers of progenitors arising following transplantation inform on the multipotential capacity of the transplanted stem cells.

In the past it was thought that some in vitro assays that tested the ability of a putative stem cell population to proliferate for extended periods of time were surrogate assays for the in vivo transplantation assay. However, with the development of gene-marking protocols, views

Stem cell ageing: does it happen and can we intervene?

on the most appropriate assays to test for stem cell function have changed, at least for HSCs. Initially, in vitro assays such as long-term culture initiating cell (LTC-IC) (Ref. 63) and high proliferative potential (HPP) cell assays (Ref. 64) were postulated to test the ability to generate additional stem and progenitor cells for variable periods of times. However, the generation of gene-marked LTC-IC proved very efficient, whereas transplantation of these same cells in an ablated host resulted in very low (<1%) levels of circulating, gene-marked cells. This suggested that in vitro assays detected progenitor cells or transient amplifying cells responsible at most for short-term engraftment (Refs 65, 66), and that a transplantation assay was the only conclusive assay for HSCs to assess their ability to give rise to cells of the lymphoid and myeloerythroid lineages.

Animal models

As the in vitro assays available for HSCs became inadequate, animal models were required. Moreover, as stem cells such as HSCs maintained their function for longer than the average human lifespan, this required models that allowed monitoring for long periods of time to assess any effect of ageing. For murine HSCs in vivo, competitive repopulation assays were performed in mice, and long-term engraftment of HSCs was assessed by secondary and tertiary transplant. However, the assessment of human HSCs was more problematic. Xenogenic hosts, particularly the immunodeficient NOD/SCID murine model (nonobese diabetic mice with severe combined immunodeficiency disease), were proposed (Ref. 67). Transplantation of HSCs in these mice resulted in terminally differentiated human cells from multiple haematopoietic lineages including B cells, immature progenitor cells, mature erythrocytes and all lineages of myeloid cells, but in low and variable numbers. In these systems multilineage engraftment of human cells could be achieved only for up to 4 months in optimised systems (Refs 66, 68, 69), and secondary transplants were very difficult to achieve. Engraftment levels of baboon haematopoietic cells in NOD/SCID mice were different to engraftment levels of the same cells in baboons (Ref. 70). In baboons, clones responsible for long-term engraftment and contributing to all lineages for nearly two years appeared only 6–8 weeks post-transplantation

(Ref. 71). This time is usually at the limit of the follow-up period in most studies where NOD/SCID mice have been used. Therefore, although NOD/SCID repopulating cells have been used as a measure of long-term repopulating cells, they probably more closely resemble short-term repopulating cells, leading to the conclusion that the NOD/SCID model may not be very useful for the study of human stem cell ageing.

The discrepancies between in vitro and in vivo assays found with HSCs may not apply to all stem cell types. Recent evidence from epithelial stem cells suggests that in vitro assays may be more predictive of what happens in vivo. Bulge cells form large colonies in vitro that can proliferate for extended periods of time. Holoclones are believed to have properties suggestive of stem cells in that they have a high colony-forming efficiency, and give rise to meroclonal and paraclonal, which have progressively less colony-forming efficiency and behave like transient amplifying cells (Ref. 55). Transplantation of single human holoclones gave rise to hair follicle, interfollicular epidermis, sebaceous gland and bulge stem cells in immunodeficient mice (Refs 72, 73) and this was long term, as shown by their ability to participate in several hair cycles and to contribute to all epithelial lineages of the hair follicle and sebaceous gland following secondary transplant (Ref. 73). If these data were to be confirmed it suggests that, in contrast to HSCs, studies on the in vitro ageing of human holoclones may be informative on the changes occurring in bulge stem cells in vivo.

For other stem cell types such a relationship has not been established and transplantation studies are only at early stages (Refs 74, 75, 76). For example, single myofibres with their associated satellite cells were transplanted into irradiated dystrophic *mdx*-nude mouse muscle. The single fibres could give rise to at least 100 new myofibres and up to tenfold more Pax-7⁺ satellite cells, a marker used to identify satellite cells (Ref. 74). These cells were able to contribute to muscle repair. However, the follow up of these experiments was short (5–8 weeks), and in a subsequent study no correlation was found between the number of Pax-7⁺ cells present in a population and its ability to regenerate muscle (Ref. 75), suggesting that Pax-7 may not be an appropriate marker for satellite cells and any

conclusion on the ageing of satellite cells needs to be taken with caution.

These studies highlight how often data on stem cells have been based on assumptions regarding their identity that more-detailed studies subsequently revealed to be incorrect. Each individual stem cell type should be properly assessed, possibly by more than one method. Regardless of the assay used, one has to bear in mind that both in vitro and in vivo assays have drawbacks. In vitro assays may be predictive of changes in the transient amplifying population rather than the stem cell population. Transplantation assays have the problem that they relate to the future potential of stem and progenitor cells, which implies that the nature of a certain stem cell type can be deduced only retrospectively on the basis of their ability to produce cells of all lineages. Any statement based on transplantation, therefore, does not tell us anything about the behaviour of a single cell but rather about the probabilistic behaviour of a population of cells. It can underestimate frequencies because it detects only those cells that not only have sufficient self-renewal potential and multipotent differentiation but also express the homing molecules necessary to seed to the tissue of interest.

Of mice and men

As a result of the problem related to the assessment of stem cell numbers and lineage potential in humans, most of the data generated on stem cell behaviour and ageing are in murine models. Yet, when considering data generated from mice to assess ageing in stem cells some points need to be kept in mind. There is compelling evidence that mice do not use the same mechanisms as humans to regulate the maximal numbers of cell division (Refs 77, 78, 79). Laboratory mice have far longer telomeres (40–60 kb) than humans (10–15 kb), and telomerase can be expressed by differentiated rodent cells such as fibroblasts (Refs 80, 81). It is likely that human stem cells undergo a far higher proliferative stress than mice. For example, it has been calculated that the number of HSCs at birth in mice and humans is similar and therefore the number of committed and mature blood cells produced by each stem cell changes with the size of the animal (Ref. 82). As a human is about 3000

times larger than a mouse and lives about 40 times longer, even considering that the lifespan of some cell types, such as erythrocytes, is shorter in mice, the proliferative stress on each human HSC is clearly higher. Therefore, the role of telomere shortening in mice is likely not to have the same relevance as in humans. In addition, it has been shown that murine cells are much more sensitive to oxidative stress and do not repair DNA damage as efficiently (Ref. 83). In murine embryo fibroblasts, the p16 and p19 pathways, mostly activated by oxidative stress, seem to be more dominant; in human cells the p21 pathway seems dominant, although the p16 pathway can also play a role (Ref. 84). Understanding these differences is essential to evaluate evidence of ageing in stem cells and to design the appropriate model to investigate it.

In this respect, the telomerase knockout mice (*mTerc*^{-/-}) (Ref. 81) may become a very useful model. The first generation of these mice do not show any distinguishing phenotype from the wild-type littermates. However, cells from the fourth-generation *mTerc*^{-/-} mice start showing significant telomere shortening and genomic instability. Cells from fifth- and sixth-generation *mTerc*^{-/-} showed p21-dependent growth arrest (Ref. 39). These mice also showed reduced lifespan, several signs of premature ageing including decreased HSC repopulation ability (Ref. 85), and reduced capacity to respond to stresses such as following haematopoietic ablation (Refs 85, 86, 87). It is possible that generating knockout mice on an *mTerc*^{-/-} background will result in models with ageing features that better resemble what is observed in humans. This is best exemplified in ataxia telangiectasia (A-T) which results from the loss of ataxia telangiectasia mutated (ATM) function and is characterised by accelerated telomere loss, progressive neurological degeneration, premature ageing and increased neoplastic transformation. Several *Atm*^{-/-} mouse strains have been generated. However, relative to ataxia telangiectasia patients they show only modest neuronal and premature ageing signs (Refs 88, 89). When *Atm*^{-/-} mice were crossed with successive generations of the *mTerc*^{-/-} mice, the model better recapitulated several aspects of the human disease such as multisystem failure and accelerated ageing (Ref. 90). This correlated with levels of telomere

dysfunction and affected stem cell reserve. Thus, mouse cell growth arrested by telomere erosion similar to human cells may be able to give a valuable insight into the role of telomere shortening or dysfunction and human stem cell ageing.

Progeroid syndromes

The long lifespan of humans makes the study of human ageing difficult to dissect. However, progeroid syndromes – mostly single gene defects that result in accelerating ageing phenotypes (Table 1) – may provide insight into some of the mechanisms of normal ageing.

For most of these syndromes it is unknown whether stem cells from these patients are affected. However, where this has been investigated, a clear association has been established between stem cell depletion, organ failure, reduced longevity and increased risk of clonal change. Studies on ataxia telangiectasia establish the link between stem cell telomere erosion, depletion of stem cell reserve and progressive multiorgan compromise with neurological degeneration, premature ageing and early death (Ref. 90). Down syndrome has emerged recently as an excellent model to study events leading to stem cell ageing. Down syndrome is associated with many of the signs of premature ageing including early abnormalities typical of Alzheimer disease, T-cell deficiency, increased incidence of myelodysplastic-type disease and leukaemia, premature reduction in skin elasticity, increased incidence of osteoporosis and early death (Refs 91, 92, 93, 94, 95).

By contrast to ataxia telangiectasia, where stem cell ageing is detected once organs have been compromised and the ageing process has ensued, the presence of trisomy 21 in Down syndrome allows the study of events occurring in the early phase of ageing development. Similarly to ataxia telangiectasia, the mean telomere restriction fragment (mTRF) of peripheral blood lymphocytes declines more rapidly in individuals with Down syndrome than in normal individuals, reflecting an accelerating HSC telomere shortening and thus HSC ageing (Ref. 96). The accelerated telomere shortening in Down syndrome is present already in fetal peripheral blood lymphocytes (Ref. 97). This is associated with stem/progenitor cell deficiency as shown by a

reduction in cells possessing the phenotype of haematopoietic progenitor cells and HSCs (detected as CD34⁺ cells) in fetal blood and bone marrow of Down syndrome children and in the number of LTC-ICs in bone marrow of children affected by Down syndrome (Ref. 97). It is of interest that both ataxia telangiectasia and Down syndrome patients have increased risk of developing malignancies, supporting the hypothesis that telomere dysfunction may overcome tumour suppressive mechanisms and predispose to genomic instability and cellular transformation.

Mechanisms of ageing in stem cells

Triggering signals

There are several indications that mechanisms of ageing apply to stem cells. We have already seen how critical telomere shortening has been shown to affect the self-renewal capacity of stem cells such as HSCs (Refs 85, 86). Epithelial stem cells seem also to be regulated by telomere length and telomerase. In telomerase-deficient mice, telomere shortening affects the function of epithelial stem cells. In particular, mobilisation of epithelial stem cells out of the hair follicle upon mitogen-induced proliferation is more affected when telomeres are critically short. This results in decreased proliferation of the stem cells in the bulge and decreased production of transient amplifying cells, with lack of hair growth (Ref. 98). Analysis of adult *mTERC*^{-/-} mice with shortened telomeres showed impaired in vitro expansion of neurospheres (cultured cell aggregates from neural stem and progenitor cells) (Ref. 99).

Very recently, it has been shown that DNA damage can result in HSC exhaustion. *Ercc1* knockout mice, which are defective in nucleotide excision repair, have decreased responses to haematopoietic stress and exhaustion of haematopoietic progenitor activity (Ref. 100). Moreover, it has been shown that increased production of reactive oxygen species (ROS) leads to bone marrow failure in *Atm*^{-/-} mice (Ref. 101).

Tumour suppressive pathways

A role for tumour suppressive pathways in self-renewal has clearly been shown for murine HSCs and to a limited extent for neural stem cells (Table 2; Fig. 3). Loss of p16 but not p19 resulted in an increase, although modest, of the

HSC pool as shown by serial transplantation (Refs 102, 103) and of the neural stem cell pool. An increase with age of the number of cells from the subventricular region that were capable of forming neurospheres in culture was reported, as well as an increase in their multipotent self-renewal ability (Ref. 104). $p18^{INK4c^{-/-}}$ ($Cdkn2c^{-/-}$) mice showed a marked increase in the number of HSCs, which retained a repopulation advantage over wild-type cells in secondary transplants (Refs 105, 106). Complete deficiency of p21 led to increased HSC proliferation and amplification of the size of the stem cell pool under homeostatic conditions in mice, but eventually led to exhaustion of the HSC pool through serial transplantation (Refs 106, 107, 108). By contrast, increased expression of p21 initiated the process of cellular senescence in response to stress. This was also seen in postnatal neural stem cells. In vitro culture of neural stem cell progenitors from $p21^{-/-}$ mice showed an increase in proliferation of the neural stem cell progenitors at a young age followed by a decline when neural stem cell cultures were derived from mice at 16 months of age, suggesting a similar phenomenon of exhaustion with age (Ref. 109).

Studies on $p53^{-/-}$ have been more difficult to carry out because of the increased incidence of tumours in those mice and death at a young age. However, studies in young $p53^{-/-}$ mice showed an increased capacity of self-renewal in HSCs. Reducing p53 levels ($p53^{-/+}$ mice) increased HSC proliferation with age compared with wild-type mice, whereas mice with a hyperactive p53 mutation showed a reduction in the number of proliferating HSCs with age (Ref. 110). Deletion of p27 resulted in an increased frequency of serially transplantable HSCs in addition to an expanded progenitor compartment (Refs 111, 112). PTEN inactivation resulted in short-term expansion of HSCs in the bone marrow but long-term decline as a result of HSCs entering the cell cycle (Ref. 113). Interestingly, PTEN mutant mice also developed a myeloproliferative disorder, reinforcing the notion that the factors limiting stem cell self-renewal have a role in malignant transformation. However, in the case of PTEN two independent PTEN-driven mechanisms seemed to drive HSC self-renewal and leukaemogenesis: rapamycin blocked the generation and maintenance of leukaemia-initiating cells but restored normal self-renewal properties of HSCs (Ref. 113).

Self-renewal genes involved in senescence pathways

Genes known to promote stem cell self-renewal have been shown to be involved in senescence pathways. It has been demonstrated that BMI-1 functions in vivo to maintain the pool of neural stem cells and HSCs by inhibiting the senescence programme through p16 (Refs 40, 41, 42, 114). Mice lacking *Bmi-1* showed induction of both p16 and p19 in the haematopoietic and neural tissue, and double deletion of p16 and p19 partially rescued the phenotype observed in *Bmi-1*-deficient mice, suggesting that p16 and p19 are downstream of *Bmi-1* (Refs 46, 115). Similarly absence of *Hoxb4*, a gene of the homeobox family considered important in regulating the size of the HSC pool (Refs 116, 117), significantly increased levels of p21 in fetal liver haematopoietic progenitors (Ref. 116). Moreover, p21 deficiency markedly enhanced the *Hoxb4*-mediated increase in HSC self-renewal (Ref. 118).

Together, these data establish the relationship between senescence pathways and stem cell self-renewal. However, there is no strong evidence that any of the factors discussed change expression with age and thus play a role in the induction of ageing in stem cells. Most studies have been carried out in animal models with germ-line gene deletions, which resulted in a persistent defect present in all cell types. It is possible that less pronounced and prolonged changes in the expression of any of these factors, as expected with ageing, would not be sufficient to promote any significant change in stem cell function. For example, conditional somatic mutagenesis of *Rb*, a central player of the senescence pathway and embryonic lethal, did not result in a great defect of the HSCs in primary and secondary transplants but only in a mild anaemia (Ref. 119). Thus, a careful analysis of the effect of these factors on stem cell self-renewal and ageing in physiological conditions is required. Moreover, if all cells harbour the defect a question to be addressed is whether some of the effects seen are intrinsic to the stem cell compartment or are related to the microenvironment. Indeed, transplantation of wild-type bone marrow in $p27^{-/-}$ mice resulted in expansion of the lymphoid compartment similar to that seen in the $p27^{-/-}$ animals. (Ref. 111), raising the possibility that the

expansion of the HSC population is in part the result of a microenvironment defect (Ref. 120).

Evidence of ageing in stem cells

These experimental limitations have shed doubts on the possibility that stem cells undergo a process of ageing. One of the main points of dispute follows the reasoning that if stem cells undergo ageing one would expect a decrease in stem cell number with age and/or a change in the number and type of progenitors produced in physiological conditions, and this has not been consistently shown. In mice, not only has a decrease in HSC numbers with an immunophenotype of the long-term repopulating cell not been observed but an absolute increase with age has been reported by several groups (Refs 16, 121, 122, 123). In other systems, estimates of changes in satellite cell number with age varied depending on the methods used, with some showing a decrease and some an increase in numbers (Refs 124, 125, 126).

However, such contrasting data have been generated by enumerating stem cells on the basis of their immunophenotype. Estimates of HSC numbers using transplantation assays are more reproducible. HSCs have been shown to undergo a loss of repopulation capacity with reduction in number and quality of progenitors under proliferative stress or with age in transplantation studies. In competitive repopulation assays, after the second or third serial transplant the host HSCs were shown to have a competitive advantage over the serially passaged donor cells (Ref. 127). When comparing HSCs from young and older mice, older animals showed reduced repopulation potential when compared with younger organisms. Moreover, the stem cell developmental programme in old age was restricted and was able to contribute mainly to the myeloid lineage. There was a reduction in the number of common lymphoid progenitors, and in gene expression profiling the transcription factors important for commitment to common lymphoid progenitors were downregulated in favour of those required for common myeloid progenitors commitment (Ref. 16). Similar data were also described with satellite cells (Ref. 126). One idea used to reconcile the opposing evidence is that the decrease seen in stem cell activity during transplantation is due to defects in stem cell homing ability coupled with an aged microenvironment and not to a decrease in stem cell numbers. To this end it has been shown that

homing efficiency of old stem cells was considerably diminished compared with stem cells of young mice (Refs 123, 128). However, this is not incompatible with the idea of an intrinsic change of the stem cell properties with age. A cell no longer fit for long-term survival could be made less competitive by its decreased homing ability. The possibility that changes in the microenvironment may also be responsible for the decreased engraftment is also not sufficient on its own. Young stem cells transplanted in an old host showed a decrease in B-cell development in the short term (Ref. 16). However, in long-term analysis B-cell development was found to be unaffected by the old microenvironment, suggesting that the defect in the microenvironment is minor (Ref. 16).

The more recent evidence that points to a role of the microenvironment as a major player in the poor regenerative capacity of satellite cells with age needs to be interpreted with caution. In young and old mice sharing a circulatory system, old muscle progenitor cells were reactivated by an unknown factor in the serum of young mice (Ref. 153). Although these data are very thought provoking, they require a more detailed characterisation of satellite cells as stem cells and their lineage progression before any conclusion can be drawn and generalised to all stem cells. Moreover, the microenvironment itself is likely to be derived from a stem cell population that undergoes ageing. For example, the mesenchymal stem cell is the progenitor of osteoblasts, adipocytes and myelosupportive stromal cells – all essential components of the bone marrow microenvironment to support the survival, proliferation and differentiation of the HSC. Mesenchymal stem cells age both in vitro and in vivo, with a decrease in the number of progenitors and multipotentiality with age of the donor (Ref. 129). It would be interesting to know whether a stem cell population is responsible for the microenvironment in which stem cells reside in other tissues outside the bone marrow.

An alternative explanation for the discrepancy observed in stem cell numbers with age may be found in the changes in gene expression occurring in the long-term repopulating stem cells with age. Analysis of gene expression profiling of this population in mice revealed that of the 317 genes found upregulated in aged stem cells, 16 have been implicated in

the genesis of various subtypes of human leukaemias (Ref. 16). Although it is recognised that most of those genes are important for stem cell self-renewal, it is tempting to speculate that increased expression of leukaemia-associated genes may be responsible for the expansion of the long-term HSC population with age and represent a state of preleukaemic transformation, which would be more easily observed in mice because of the weaker protection of tumour suppressor mechanisms. This would lead to the expansion of cells with the phenotype of long-term repopulating stem cells but that have lost the ability to appropriately differentiate and repopulate the haematopoietic system. Indeed, in the same study the number of cells with a phenotype of long-term repopulating cells, from which common myeloid progenitors and common lymphoid progenitors derive, increased with serial transplant, suggesting that this population was transplantable and had some stem cell properties. However, the balance between myeloid and lymphoid cells was shown to be altered following serial transplantation, and haematopoietic stem cell differentiation in the secondary transplant was skewed towards myeloid cells at the expense of lymphoid cells (Ref. 16), suggesting that the long-term repopulating stem cells were undergoing an altered differentiation program.

A careful examination of human stem cell number and quality is therefore required. Nevertheless, although data on the ageing of human stem cells are limited and mostly indirect, they all favour a decrease in stem cell number and quality with age. Most evidence comes from human HSCs. The incidence of anaemia and neutropaenia increases in old age for unknown reasons (Ref. 130), the amount of active bone marrow in the pelvis sternum and vertebrae decreases from childhood to old age (Ref. 131), the number of CD34⁺ circulating in blood is reduced (Ref. 132), and the number and function of CD34⁺ cells harvested from bone marrow declines with age (Ref. 133). In women heterozygous for X-linked glucose-6-phosphate dehydrogenase, the chimaerism remained balanced until middle age but was heavily skewed towards one active X-linked allele or the other in old age, consistent with a decline in the number of recruitable stem cells (Ref. 134). Ho et al. (Ref. 133) reported that over 20 years of experience, age was the main

variable and worst prognostic factors for clinical outcome of transplantation. These data all favour the notion of a decrease in stem cell number in humans with age.

This is supported also by the presence of mechanisms important in cellular ageing. Despite the fact that HSCs produce telomerase, telomeres of stem cells have been seen to progressively shorten with age (Refs 135, 136, 137, 138) and following haematopoietic stress, such as in HSC transplantation (Refs 139, 140). This suggests that telomerase is expressed in amounts insufficient to prevent telomere erosion but sufficient to delay it (Ref. 141). The importance of telomere shortening in HSC ageing and organ failure is well represented in individuals suffering from dyskeratosis congenita: this arises from mutations in one of the components of the telomerase enzyme and results in reduced levels of telomerase activity, shorter telomeres and bone marrow failure as one of the principal cause of death (Ref. 142). These data suggest that although more accurate studies in appropriate models are required, human stem cells can undergo a process of ageing, which may have important outcomes at least in certain pathological conditions.

Outstanding research questions on stem cell ageing and therapeutic intervention

Organismal ageing is characterised by functional decline of tissues and organs with age and this is most obvious in situations of injury or stress. As stem cells are involved in the repair and maintenance of tissues, questions arise as to how important the role of stem cells is in ageing in the decline of tissue function and whether there is potential for intervention.

There is clearly no evidence that stem cells are the master switch of tissue function and have any effect on longevity. This is a very difficult hypothesis to test as ageing is a global process affecting multiple organs. However, it is of interest that in a study of men and women of 60–97 years of age it was observed that telomere length in peripheral blood, which has been shown to reflect telomere length of the HSC pool (Ref. 137), was related to subsequent survival, with longer telomeres associated with a significantly lower risk of death (Ref. 143). Moreover, in progeroid syndromes where stem cells have been studied a clear association among accelerated telomere shortening,

decreased number of stem cells, organ failure and lifespan is present (Refs 90, 97). Further studies are required to ascertain the impact of stem cell ageing in physiological conditions as opposed to conditions of stress only.

One of the arguments that place stem cells at the low level of contribution in the development of the ageing phenotype is the reasoning that tissues such as the central nervous system have low turnover and the majority of neurons are not replaced, despite the fact that the central nervous system is severely affected by ageing. Although there may be differences among stem cell types in the requirements for self-renewal, the view that there is no cell replacement in some tissues is outdated. Even stem cells such as neural stem cells, which were thought to be inactive in postnatal life, are now known to contribute to neuron replacement in some brain regions under steady-state conditions throughout life (Ref. 144), suggesting that ageing may have a role in all stem cell types. A more careful understanding of tissue turnover and the role that stem cells have in it may reveal that stem cell dysfunction is involved in a wider number of degenerative pathologies than previously thought.

Regardless of the impact that stem cell ageing can have on organ failure and longevity, the ability to intervene and increase even modestly the number of stem cells in the pool may have great impact in areas of chronic diseases or regenerative medicine. Pathologies such as ataxia telangiectasia show stem cell defects and organ failure due to increased production of ROS. Very recently, treatment with antioxidant restored the reconstitution ability of ATM-deficient HSCs and prevented bone marrow failure (Ref. 101). Limited proliferation and favoured differentiation has been shown to compromise the ex vivo expansion and restrict the broader use of adult stem cells. *mTerc*^{-/-} mice with *p21*^{-/-} showed an increase in the stem cell pool with no further incidence of cancer (Ref. 107), suggesting that temporary inhibition of p21 expression may extend the self-renewal property of stem cells sufficiently to allow rescue of tissue function in a situation of limited regeneration capacity available or when this tends to be lost such as during in vitro culture of HSCs. Indeed, valproic acid was used to increase the proliferation and self-renewal of HSCs through downregulation of

p21 (Refs 145, 146). The temporary inhibition of p21 expression allowed preservation of the self-renewal capacity of HSCs during ex vivo culture and gene modification. Therapeutic strategies developed so far are few but they are a proof of principle of the importance of an in-depth understanding of the mechanisms involved in stem cell ageing and the potential for intervention. A better understanding of the molecular basis of stem cell ageing will uncover novel molecules capable of extending tissue survival and repair.

Most of the data available on the molecular players in stem cell ageing are derived from transgenic animals. Considerable more information is needed on the identity of the molecular pathways that play a role in ageing of human stem cells in physiological conditions. However, the uncovering of these pathways will open up opportunities for drug discovery and strategies to identify compounds that can be used to manipulate stem cells for therapeutic or biotechnology purposes. Progress is well under way with proof-of-concept approaches in small-molecule manipulation of both embryonic stem cells and adult tissue stem/progenitor cells (Refs 147, 148, 149). These early studies are pointing the way to a bright future for ageing research and stem cell biology.

Acknowledgements and funding

Research in the authors' laboratories is supported by Cancer Research UK, University of Glasgow and European Community grant LSHC-CT-2004-502943, Strategic Promotion of Ageing Research Capacity, Biotechnology and Biological Sciences Research Council, Leukaemia Research Fund, and the University of Sheffield.

References

- 1 Thomson, J.A. et al. (1998) Embryonic stem cell lines derived from human blastocysts. *Science* 282, 1145-1147
- 2 Reubinoff, B.E. et al. (2000) Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. *Nat Biotechnol* 18, 399-404
- 3 Weissman, I.L. (2000) Stem cells: units of development, units of regeneration, and units in evolution. *Cell* 100, 157-168
- 4 Watt, F.M. (2000) Epidermal stem cells as targets for gene transfer. *Hum Gene Ther* 11, 2261-2266
- 5 Whitehead, R.H. et al. (1999) Clonogenic growth of epithelial cells from normal colonic mucosa from

- both mice and humans. *Gastroenterology* 117, 858-865
- 6 Potten, C.S. et al. (2003) Identification of a putative intestinal stem cell and early lineage marker; *musashi-1*. *Differentiation* 71, 28-41
- 7 Wagers, A.J. and Conboy, I.M. (2005) Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis. *Cell* 122, 659-667
- 8 Gage, F.H. (2000) Mammalian neural stem cells. *Science* 287, 1433-1438
- 9 Alison, M. (2002) Hepatic stem cells. *Transplant Proc* 34, 2702-2705
- 10 Clarke, R.B. (2005) Isolation and characterization of human mammary stem cells. *Cell Proliferation* 38, 375-386
- 11 Lechner, A. and Habener, J.F. (2003) Stem/progenitor cells derived from adult tissues: potential for the treatment of diabetes mellitus. *Am J Physiol Endocrinol Metab* 284, E259-266
- 12 Siminovitch, L., Till, J.E. and McCulloch, E.A. (1964) Decline In Colony-Forming Ability Of Marrow Cells Subjected To Serial Transplantation Into Irradiated Mice. *J Cell Physiol* 64, 23-31
- 13 Rando, T.A. (2007) The immortal strand hypothesis: segregation and reconstruction. *Cell* 129, 1239-1243
- 14 Lansdorp, P.M. (2007) Immortal strands? Give me a break. *Cell* 129, 1244-1247
- 15 Wright, L.S. et al. (2003) Gene expression in human neural stem cells: effects of leukemia inhibitory factor. *J Neurochem* 86, 179-195
- 16 Rossi, D.J. et al. (2005) Cell intrinsic alterations underlie hematopoietic stem cell aging. *Proc Natl Acad Sci U S A* 102, 9194-9199
- 17 Rossi, D.J. et al. (2007) Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. *Nature* 447, 725
- 18 Campisi, J. (2001) Cellular senescence as a tumor-suppressor mechanism. *Trends Cell Biol* 11, S27-31
- 19 Sharpless, N.E. and DePinho, R.A. (2004) Telomeres, stem cells, senescence, and cancer. *J Clin Invest* 113, 160-168
- 20 Pelicci, P.G. (2004) Do tumor-suppressive mechanisms contribute to organism aging by inducing stem cell senescence? *J Clin Invest* 113, 4-7
- 21 Gil, J. and Peters, G. (2006) Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. *Nat Rev Mol Cell Biol* 7, 667-677
- 22 Dimri, G.P. et al. (1995) A biomarker that identifies senescent human cells in culture and in aging skin in vivo. *Proc Natl Acad Sci U S A* 92, 9363-9367
- 23 Paradis, V. et al. (2001) Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. *Hum Pathol* 32, 327-332
- 24 Lechel, A. et al. (2005) The cellular level of telomere dysfunction determines induction of senescence or apoptosis in vivo. *EMBO Rep* 6, 275-281
- 25 Wiemann, S.U. et al. (2002) Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. *Faseb J* 16, 935-942
- 26 Satyanarayana, A. et al. (2003) Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. *Embo J* 22, 4003-4013
- 27 Sharpless, N.E. and DePinho, R.A. (2004) Telomeres, stem cells, senescence, and cancer. *J Clin Invest* 113, 160-168
- 28 Kim, W.Y. and Sharpless, N.E. (2006) The regulation of INK4/ARF in cancer and aging. *Cell* 127, 265-275
- 29 Serrano, M. et al. (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of 53 and p16INK4a. *Cell* 88, 593-602
- 30 Maehama, T. and Dixon, J.E. (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. *J Biol Chem* 273, 13375-13378
- 31 Di Cristofano, A. and Pandolfi, P.P. (2000) The multiple roles of PTEN in tumor suppression. *Cell* 100, 387-390
- 32 Hayflick, L. and Moorhead, P.S. (1961) The serial cultivation of human diploid cell strains. *Exp Cell Res* 25, 585-621
- 33 Blackburn, E.H. (2005) Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. *FEBS Lett* 579, 859-862
- 34 Harley, C.B., Futcher, A.B. and Greider, C.W. (1990) Telomeres shorten during ageing of human fibroblasts. *Nature* 345, 458-460
- 35 de Lange, T. (2002) Protection of mammalian telomeres. *Oncogene* 21, 532-540
- 36 Geserick, C. and Blasco, M.A. (2006) Novel roles for telomerase in aging. *Mech Ageing Dev* 127, 579-583
- 37 Sherr, C.J. and DePinho, R.A. (2000) Cellular senescence: mitotic clock or culture shock? *Cell* 102, 407-410
- 38 Drayton, S. and Peters, G. (2002) Immortalisation and transformation revisited. *Curr Opin Genet Dev* 12, 98-104
- 39 Chin, L. et al. (1999) 53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. *Cell* 97, 527-538

- 40 Molofsky, A.V. et al. (2003) Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. *Nature* 425, 962-967
- 41 Iwama, A. et al. (2004) Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. *Immunity* 21, 843-851
- 42 Park, I.K. et al. (2003) Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. *Nature* 423, 302-305
- 43 Jacobs, J.J. et al. (1999) The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. *Nature* 397, 164-168
- 44 Itahana, K. et al. (2003) Control of the replicative life span of human fibroblasts by 16 and the polycomb protein Bmi-1. *Mol Cell Biol* 23, 389-401
- 45 Guney, I., Wu, S. and Sedivy, J.M. (2006) Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and 16(INK4a). *Proc Natl Acad Sci U S A* 103, 3645-3650
- 46 Bruggeman, S.W. et al. (2005) Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. *Genes Dev* 19, 1438-1443
- 47 Cantley, L.C. and Neel, B.G. (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. *Proc Natl Acad Sci U S A* 96, 4240-4245
- 48 Stiles, B. et al. (2004) PTENless means more. *Dev Biol* 273, 175-184
- 49 Kondo, M. et al. (2003) Biology of hematopoietic stem cells and progenitors: implications for clinical application. *Annu Rev Immunol* 21, 759-806
- 50 Civin, C.I. et al. (1990) Positive stem cell selection—basic science. *Prog Clin Biol Res* 333, 387-401; discussion 402
- 51 Brugger, W. et al. (1994) Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. *Blood* 84, 1421-1426
- 52 Bhatia, M. et al. (1997) Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. *Proc Natl Acad Sci U S A* 94, 5320-5325
- 53 Glimm, H. et al. (2001) Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice. *J Clin Invest* 107, 199-206
- 54 Lajtha, L.G. (1979) Stem cell concepts. *Differentiation* 14, 23-34
- 55 Barrandon, Y. and Green, H. (1987) Three clonal types of keratinocyte with different capacities for multiplication. *Proc Natl Acad Sci U S A* 84, 2302-2306
- 56 Morrison, S.J. et al. (1997) Identification of a lineage of multipotent hematopoietic progenitors. *Development* 124, 1929-1939
- 57 Lavker, R.M. et al. (1993) Hair follicle stem cells: their location, role in hair cycle, and involvement in skin tumor formation. *J Invest Dermatol* 101, 16S-26S
- 58 Tumber, T. et al. (2004) Defining the epithelial stem cell niche in skin. *Science* 303, 359-363
- 59 Tamaki, S. et al. (2002) Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. *J Neurosci Res* 69, 976-986
- 60 Quirici, N. et al. (2002) Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies. *Exp Hematol* 30, 783-791
- 61 Bensidhoum, M. et al. (2004) Homing of in vitro expanded Stro-1- or Stro-1+ human mesenchymal stem cells into the NOD/SCID mouse and their role in supporting human CD34 cell engraftment. *Blood* 103, 3313-3319
- 62 Dennis, J.E. et al. (2002) The STRO-1+ marrow cell population is multipotential. *Cells Tissues Organs* 170, 73-82
- 63 Szilvassy, S.J. et al. (1990) Quantitative assay for totipotent reconstituting hematopoietic stem cells by a competitive repopulation strategy. *Proc Natl Acad Sci U S A* 87, 8736-8740
- 64 McNiece, I.K. et al. (1990) Colony-forming cells with high proliferative potential (HPP-CFC). *Int J Cell Cloning* 8, 146-160
- 65 Bhatia, M. et al. (1998) A newly discovered class of human hematopoietic cells with SCID-repopulating activity. *Nat Med* 4, 1038-1045
- 66 Larochelle, A. et al. (1996) Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. *Nat Med* 2, 1329-1337
- 67 Bonnet, D. (2002) Haematopoietic stem cells. *J Pathol* 197, 430-440
- 68 Larochelle, A. et al. (1995) Engraftment of immune-deficient mice with primitive hematopoietic cells from beta-thalassemia and sickle cell anemia patients: implications for evaluating human gene therapy protocols. *Hum Mol Genet* 4, 163-172

- 69 Cashman, J. et al. (1997) Sustained proliferation, multi-lineage differentiation and maintenance of primitive human haemopoietic cells in NOD/SCID mice transplanted with human cord blood. *Br J Haematol* 98, 1026-1036
- 70 Horn, P.A. et al. (2003) Distinct hematopoietic stem/progenitor cell populations are responsible for repopulating NOD/SCID mice compared with nonhuman primates. *Blood* 102, 4329-4335
- 71 Schmidt, M. et al. (2002) Polyclonal long-term repopulating stem cell clones in a primate model. *Blood* 100, 2737-2743
- 72 Blanpain, C. et al. (2004) Self-renewal, multipotency, and the existence of two cell populations within an epithelial stem cell niche. *Cell* 118, 635-648
- 73 Claudinot, S. et al. (2005) Long-term renewal of hair follicles from clonogenic multipotent stem cells. *Proc Natl Acad Sci U S A* 102, 14677-14682
- 74 Collins, C.A. et al. (2005) Stem cell function, self-renewal, and behavioral heterogeneity of cells from the adult muscle satellite cell niche. *Cell* 122, 289-301
- 75 Collins, C.A. et al. (2007) A population of myogenic stem cells that survives skeletal muscle aging. *Stem Cells* 25, 885-894
- 76 Ostenfeld, T. et al. (2000) Human neural precursor cells express low levels of telomerase in vitro and show diminishing cell proliferation with extensive axonal outgrowth following transplantation. *Exp Neurol* 164, 215-226
- 77 Wright, W.E. and Shay, J.W. (2001) Cellular senescence as a tumor-protection mechanism: the essential role of counting. *Curr Opin Genet Dev* 11, 98-103
- 78 Wright, W.E. and Shay, J.W. (2002) Historical claims and current interpretations of replicative aging. *Nat Biotechnol* 20, 682-688
- 79 Smogorzewska, A. and de Lange, T. (2002) Different telomere damage signaling pathways in human and mouse cells. *Embo J* 21, 4338-4348
- 80 Prowse, K.R. and Greider, C.W. (1995) Developmental and tissue-specific regulation of mouse telomerase and telomere length. *Proc Natl Acad Sci U S A* 92, 4818-4822
- 81 Blasco, M.A. et al. (1997) Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. *Cell* 91, 25-34
- 82 Abkowitz, J.L. et al. (2002) Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. *Blood* 100, 2665-2667
- 83 Parrinello, S. et al. (2003) Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts. *Nat Cell Biol* 5, 741-747
- 84 Itahana, K., Campisi, J. and Dimri, G.P. (2004) Mechanisms of cellular senescence in human and mouse cells. *Biogerontology* 5, 1-10
- 85 Samper, E. et al. (2002) Long-term repopulating ability of telomerase-deficient murine hematopoietic stem cells. *Blood* 99, 2767-2775
- 86 Rudolph, K.L. et al. (1999) Longevity, stress response, and cancer in aging telomerase-deficient mice. *Cell* 96, 701-712
- 87 Lee, H.W. et al. (1998) Essential role of mouse telomerase in highly proliferative organs. *Nature* 392, 569-574
- 88 Barlow, C. et al. (1996) *Atm*-deficient mice: a paradigm of ataxia telangiectasia. *Cell* 86, 159-171
- 89 Xu, Y. et al. (1996) Targeted disruption of *ATM* leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. *Genes Dev* 10, 2411-2422
- 90 Wong, K.K. et al. (2003) Telomere dysfunction and *Atm* deficiency compromises organ homeostasis and accelerates ageing. *Nature* 421, 643-648
- 91 Epstein, C.J. (1995) Down syndrome (Trisomy 21) (Scriver, C.A. et al., series eds), pp. 749-794, McGraw-Hill, New York
- 92 Nespoli, L. et al. (1993) Immunological features of Down's syndrome: a review. *J Intellect Disabil Res* 37, 543-551
- 93 Rumble, B. et al. (1989) Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. *N Engl J Med* 320, 1446-1452
- 94 Angelopoulou, N. et al. (2000) Bone mineral density and muscle strength in young men with mental retardation (with and without Down syndrome). *Calcif Tissue Int* 66, 176-180
- 95 Creutzig, U. et al. (1996) Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. *Leukemia* 10, 1677-1686
- 96 Vaziri, H. et al. (1993) Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes. *Am J Hum Genet* 52, 661-667
- 97 Holmes, D.K. et al. (2006) Hematopoietic progenitor cell deficiency in fetuses and children affected by Down's syndrome. *Exp Hematol* 34, 1611-1615
- 98 Flores, I., Cayuela, M.L. and Blasco, M.A. (2005) Effects of telomerase and telomere length on

- epidermal stem cell behavior. *Science* 309, 1253-1256
- 99 Ferron, S. et al. (2004) Telomere shortening and chromosomal instability abrogates proliferation of adult but not embryonic neural stem cells. *Development* 131, 4059-4070
- 100 Prasher, J.M. et al. (2005) Reduced hematopoietic reserves in DNA interstrand crosslink repair-deficient *Ercc1*^{-/-} mice. *Embo J* 24, 861-871
- 101 Ito, K. et al. (2006) Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. *Nat Med* 12, 446-451
- 102 Stepanova, L. and Sorrentino, B.P. (2005) A limited role for p16Ink4a and p19Arf in the loss of hematopoietic stem cells during proliferative stress. *Blood* 106, 827-832
- 103 Janzen, V. et al. (2006) Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. *Nature* 443, 421-426
- 104 Molofsky, A.V. et al. (2006) Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. *Nature* 443, 448-452
- 105 Yuan, Y. et al. (2004) In vivo self-renewing divisions of haematopoietic stem cells are increased in the absence of the early G1-phase inhibitor, p18INK4C. *Nat Cell Biol* 6, 436-442
- 106 Yu, H. et al. (2006) Hematopoietic stem cell exhaustion impacted by p18 INK4C and p21 Cip1/Waf1 in opposite manners. *Blood* 107, 1200-1206
- 107 Choudhury, A.R. et al. (2007) *Cdkn1a* deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. *Nat Genet* 39, 99-105
- 108 Cheng, T. et al. (2000) Hematopoietic stem cell quiescence maintained by p21cip1/waf1. *Science* 287, 1804-1808
- 109 Kippin, T.E. et al. (2004) Neural stem cells show bidirectional experience-dependent plasticity in the perinatal mammalian brain. *J Neurosci* 24, 2832-2836
- 110 Dumble, M. et al. (2007) The impact of altered p53 dosage on hematopoietic stem cell dynamics during aging. *Blood* 109, 1736-1742
- 111 Walkley, C.R. et al. (2005) Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells. *Nat Cell Biol* 7, 172-178
- 112 Cheng, T. et al. (2000) Stem cell repopulation efficiency but not pool size is governed by p27(kip1). *Nat Med* 6, 1235-1240
- 113 Zhang, J. et al. (2006) PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention. *Nature* 441, 518-522
- 114 Lessard, J. and Sauvageau, G. (2003) Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. *Nature* 423, 255-260
- 115 Molofsky, A.V. et al. (2005) Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. *Genes Dev* 19, 1432-1437
- 116 Brun, A.C. et al. (2004) Hoxb4-deficient mice undergo normal hematopoietic development but exhibit a mild proliferation defect in hematopoietic stem cells. *Blood* 103, 4126-4133
- 117 Bjornsson, J.M. et al. (2003) Reduced proliferative capacity of hematopoietic stem cells deficient in Hoxb3 and Hoxb4. *Mol Cell Biol* 23, 3872-3883
- 118 Miyake, N. et al. (2006) HOXB4-induced self-renewal of hematopoietic stem cells is significantly enhanced by p21 deficiency. *Stem Cells* 24, 653-661
- 119 Walkley, C.R. and Orkin, S.H. (2006) Rb is dispensable for self-renewal and multilineage differentiation of adult hematopoietic stem cells. *Proc Natl Acad Sci U S A* 103, 9057-9062
- 120 Chien, W.M. et al. (2006) Genetic mosaics reveal both cell-autonomous and cell-nonautonomous function of murine p27Kip1. *Proc Natl Acad Sci U S A* 103, 4122-4127
- 121 Sudo, K. et al. (2000) Age-associated characteristics of murine hematopoietic stem cells. *J Exp Med* 192, 1273-1280
- 122 Pearce, D.J. et al. (2006) Age-dependent increase in side population distribution within hematopoiesis: implications for our understanding of the mechanism of aging. *Stem Cells* 5, 828-835
- 123 Morrison, S.J. et al. (1996) The aging of hematopoietic stem cells. *Nat Med* 2, 1011-1016
- 124 Gibson, M.C. and Schultz, E. (1983) Age-related differences in absolute numbers of skeletal muscle satellite cells. *Muscle Nerve* 6, 574-580
- 125 Conboy, I.M. et al. (2003) Notch-mediated restoration of regenerative potential to aged muscle. *Science* 302, 1575-1577
- 126 Brack, A.S., Bildsoe, H. and Hughes, S.M. (2005) Evidence that satellite cell decrement contributes to preferential decline in nuclear number from large fibres during murine age-related muscle atrophy. *J Cell Sci* 118, 4813-4821
- 127 Ogden, D.A. and Mickliem, H.S. (1976) The fate of serially transplanted bone marrow cell populations from young and old donors. *Transplantation* 22, 287-293
- 128 Liang, Y., Van Zant, G. and Szilvassy, S.J. (2005) Effects of aging on the homing and engraftment of

- murine hematopoietic stem and progenitor cells. *Blood* 106, 1479-1487
- 129 Baxter, M.A. et al. (2004) Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. *Stem Cells* 22, 675-682
- 130 Lipschitz, D.A., Mitchell, C.O. and Thompson, C. (1981) The anemia of senescence. *Am J Hematol* 11, 47-54
- 131 Harstock, R.J., Smith, E.B. and Ketter, C.S. (1965) Normal variation with aging of the amount of hematopoietic tissue in bone marrow from anterior iliac crest. *Am J Clin Pathol* 43, 325-333
- 132 Bagnara, G.P. et al. (2000) Hemopoiesis in healthy old people and centenarians: well-maintained responsiveness of CD34+ cells to hemopoietic growth factors and remodeling of cytokine network. *J Gerontol A Biol Sci Med Sci* 55, B61-66; discussion B67-70
- 133 Ho, A.D., Wagner, W. and Mahlknecht, U. (2005) Stem cells and ageing. The potential of stem cells to overcome age-related deteriorations of the body in regenerative medicine. *EMBO Rep* 6 Spec No, S35-38
- 134 Gale, R.E. et al. (1997) Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. *Br J Haematol* 98, 512-519
- 135 Morrison, S.J. et al. (1996) Telomerase activity in hematopoietic cells is associated with self-renewal potential. *Immunity* 5, 207-216
- 136 Lansdorp, P.M. (1995) Telomere length and proliferation potential of hematopoietic stem cells. *J Cell Sci* 108, 1-6
- 137 Rufer, N. et al. (1998) Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. *Nat Biotechnol* 16, 743-747
- 138 Vaziri, H. et al. (1994) Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. *Proc Natl Acad Sci U S A* 91, 9857-9860
- 139 Wynn, R. et al. (1999) Telomere shortening in leucocyte subsets of long-term survivors of allogeneic bone marrow transplantation. *Br J Haematol* 105, 997-1001
- 140 Notaro, R. et al. (1997) In vivo telomere dynamics of human hematopoietic stem cells. *Proc Natl Acad Sci U S A* 94, 13782-13785
- 141 Allsopp, R.C. et al. (2003) Telomerase is required to slow telomere shortening and extend replicative lifespan of HSCs during serial transplantation. *Blood* 102, 517-520
- 142 Mason, P.J., Wilson, D.B. and Bessler, M. (2005) Dyskeratosis congenita – a disease of dysfunctional telomere maintenance. *Curr Mol Med* 5, 159-170
- 143 Cawthon, R.M. et al. (2003) Association between telomere length in blood and mortality in people aged 60 years or older. *Lancet* 361, 393-395
- 144 Kruger, G.M. and Morrison, S.J. (2002) Brain repair by endogenous progenitors. *Cell* 110, 399-402
- 145 De Felice, L. et al. (2005) Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. *Cancer Res* 65, 1505-1513
- 146 Bug, G. et al. (2005) Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. *Cancer Res* 65, 2537-2541
- 147 Chen, S. et al. (2006) Self-renewal of embryonic stem cells by a small molecule. *Proc Natl Acad Sci U S A* 103, 17266-17271
- 148 Trowbridge, J.J. et al. (2006) Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. *Nat Med* 12, 89-98
- 149 Sato, N. et al. (2004) Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. *Nat Med* 10, 55-63
- 150 Halaschek-Wiener, J. and Brooks-Wilson, A. (2007) Progeria of stem cells: stem cell exhaustion in Hutchinson-Gilford progeria syndrome. *J Gerontol A Biol Sci Med Sci* 62, 3-8
- 151 Ramirez, C.L. et al. (2007) Human progeroid syndromes, aging and cancer: new genetic and epigenetic insights into old questions. *Cell Mol Life Sci* 64, 155-170
- 152 Kudlow, B.A., Kennedy, B.K. and Monnat, R.J., Jr. (2007) Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. *Nat Rev Mol Cell Biol* 8, 394-404
- 153 Conboy, I.M. et al. (2005) Rejuvenation of aged progenitor cells by exposure to a young systemic environment. *Nature* 433, 760-764

Further reading, resources and contacts

Stem cell society

The International Society for Stem Cell Research (ISSCR) website has excellent links on stem cells:

<http://www.isscr.org>

Protocols and resources

Abcam, Miltenyi Biotech, Stem Cell Technologies and BD Biosciences have antibody and specialised reagents for the isolation and culture of murine and human stem cells:

<http://www.abcam.com/>

<http://www.miltenyibiotec.com/>

<http://www.stemcell.com/>

<http://www.bdbiosciences.com/>

Research centres and biopharmaceutical companies

<http://www.nia.nih.gov/> (National Institute on Aging)

<http://www.buckinstitute.org/site/> (Buck Institute for Age Research)

<http://www.barshop.uthscsa.edu/> (The Sam and Ann Barshop Institute for Longevity and Aging Studies)

<http://www.cnio.es/ing/grupos/plantillas/presentacion.asp?grupo=50004259> (Maria Blasco, National Center of Biotechnology)

<http://www.mc.uky.edu/physiology/people/faculty/vanzant%20research.asp> (Gary Van Zant, University of Kentucky)

<http://www.geron.com/> (Geron corporation)

Features associated with this article

Figures

Figure 1. Proposed self-renewal and differentiation capacity in ageing adult stem cells.

Figure 2. Model of stem cell proliferation and ageing.

Figure 3. Examples of cell signalling pathways implicated in adult stem cell ageing.

Figure 4. Identification of stem cells.

Tables

Table 1. Progeroid syndromes and the investigation of stem cell ageing.

Table 2. Effects of changes in expression of tumour suppressor genes in stem cells.

Citation details for this article

Ilaria Bellantuono and W. Nicol Keith (2007) Stem cell ageing: does it happen and can we intervene? Expert Rev. Mol. Med. Vol. 9, Issue 31, November 2007, DOI: 10.1017/S146239940700049X